Primary Site >> Colorectal Cancer

Gene >> COMP

Journal: Acta Physiol Hung. 1992;79(2):183-96.
Title: Pharmacokinetics of radiopharmaceuticals.
Author: Janoki, G A|Kerekes, A
PMID: 1304681
Journal: J Clin Oncol. 1993 Jun;11(6):1024-32.
Title: Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group.
Author: Anderson, J R|Jenkin, R D|Wilson, J F|Kjeldsberg, C R|Sposto, R|Chilcote, R R|Coccia, P F|Exelby, P R|Siegel, S|Meadows, A T
PMID: 8501488
Journal: Arch Pharm Res. 1999 Apr;22(2):151-6.
Title: Cytotoxicity of two novel cisplatin analogues, (CPA)2Pt[DOLYM] and (DACH)Pt[DOLYM], to human cancer cells in vitro.
Author: Choi, S U|Kim, K H|Choi, E J|Park, S H|Kim, K M|Shon, Y S|Lee, C O
PMID: 10230505
Journal: J Proteome Res. 2013 Dec 6;12(12):5996-6003.
Title: Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma.
Author: Lin, De|Alborn, William E|Slebos, Robbert J C|Liebler, Daniel C
PMID: 24224610
Journal: Colorectal Dis. 2014 Jul;16(7):O223-33.
Title: Health-related quality of life after surgery for advanced and recurrent rectal cancer: a nationwide prospective study.
Author: Thaysen, H V|Jess, P|Rasmussen, P C|Nielsen, M B|Laurberg, S
PMID: 24373460
Journal: J Exp Clin Cancer Res. 2018 Sep 19;37(1):231.
Title: HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Author: Li, Qing|Wang, Cong|Wang, Yufeng|Sun, Liankang|Liu, Zhikui|Wang, Liang|Song, Tao|Yao, Yingmin|Liu, Qingguang|Tu, Kangsheng
PMID: 30231922